Aerocrine enters collaboration for improved treatment of asthma and intestinal diseases

Aerocrine enters collaboration for improved treatment of asthma and intestinal
diseases

SOLNA - 15 October, 2007 - Aerocrine AB (OMX Nordic Exchange: AERO) announces
that it has become a partner in a program for the development of diagnostic
methods for allergies, asthma and food hypersensitivity.

The purpose of the research program is to develop simple diagnostic methods for
allergies, asthma and food hypersensitivity for use in specialist and primary
healthcare. The objective of the program is to develop and clinically assess
equipment to measure inflammation in the peripheral airways by means of exhaled
air, and equipment to ascertain the type and degree of intestinal inflammation
by means of rectal gas and fluid samples. Efforts will also seek to enable the
measurement of various types of antibodies and other inflammation indicators in
blood, saliva and intestinal secretions. With its new product NIOX® Flex,
Aerocrine also advances the possibility of determining which area of the airways
is inflamed. This can be of great importance for selecting treatment in patients
with asthma.

Partners in the program are Phadia AB, Aerocrine AB, Alimenta Medical AB,
Uppsala University, as well as Uppsala University Hospital. VINNOVA (Swedish
Governmental Agency for Innovation Systems) sponsors the project by covering
half of its costs, while the industrial partners are responsible for the
remainder.

Combined, inflammatory diseases account for a significant proportion of
healthcare costs and lost production in society. These diseases also cause
extensive human suffering and impaired quality of life. In addition, certain
inflammatory diseases have increased markedly over recent decades, including
asthma and celiac disease. In many cases, effective medical treatments are
available, not least for asthma, and the correct elimination diet can result in
a total lack of symptoms from food hypersensitivity. However, the lack of simple
and reliable measurement methods limits diagnosis and treatment monitoring.

For more information, contact:

Kjell Alving, Director, Scientific and Medical Affairs: telephone: +46 70 659
8870

About Aerocrine
Aerocrine AB is a clinically based medical technology corporation dedicated to
improved asthma management and care. Aerocrine was listed on the Stockholm Stock
Exchange on 15 June, 2007. The company is marketing NIOX® Flex on a worldwide
basis and is also marketing NIOX MINO®, representing a new generation of
hand-held devices, in Europe. Both products are tailored for rapid, non-invasive
control of the inflammatory status in the airways and may play a critical role
for optimized asthma care and disease control. Aerocrine is located in Sweden
with wholly owned subsidiaries in the US, UK and Germany.